The failure of dabigatran to prevent thromboembolic complications in patients with mechanical heart valves is most likely explained by its mechanism of action, an international expert says. Professor John Eikelboom from McMaster University in Ontario, Canada, told delegates at the Blood 2019 meeting in Perth that patients with mechanical heart valves needed lifelong anticoagulation in ...
Why DOACs don’t work in patients with valve replacements
By Nicola Garrett
23 Oct 2019